Avista Pharma Solutions completed acquisition of Solid Form Solutions located in Edinburgh, Scotland. Solid Form Solutions provider of solid state chemistry and crystallization development services for clients in the pharmaceutical industry. The collaboration enhances Avista Pharma’s existing solid phase chemistry services thereby offering access to analytical development to API and drug product manufacturing. Solid Form Solutions will continue operating in its Edinburgh, Scotland facility, providing clients with services including salt screening and selection, co-crystal and polymorph screening, crystallization development, and other analytical testing and development.
Patrick Walsh,CEO of Avista Pharma said “Solid Form Solutions has a reputation of providing valuable early phase services that significantly reduce risk and improve speed later during the drug development process.”
Dr. Stephen Watt, CEO of Solid Form Solutions, said, “Solid Form Solutions has been built on deep scientific expertise and an intense focus on the needs of our clients, and those characteristics directly align with our colleagues at Avista Pharma. We are excited to be able to bring a broader array of drug development services to our clients while avoiding the time and costs associated with tech transfer to a third-party.”